Mani Foroohar
Stock Analyst at Leerink Partners
(3.42)
# 989
Out of 5,124 analysts
170
Total ratings
52.13%
Success rate
3.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $16 → $20 | $13.57 | +47.38% | 11 | Dec 15, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $85 → $100 | $79.67 | +25.52% | 16 | Dec 15, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $75 → $86 | $78.24 | +9.93% | 16 | Dec 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $370 → $351 | $400.17 | -12.29% | 12 | Dec 15, 2025 | |
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $30.86 | -41.67% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $9.61 | +108.12% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.46 | +102.31% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $21.31 | -53.07% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.20 | +42.86% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $7.32 | +268.85% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $72 | $20.16 | +257.14% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $6.00 | +183.33% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $78.07 | -37.24% | 11 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $15.95 | +37.93% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.59 | +3.30% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $17.98 | +61.29% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $4.67 | -14.35% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $8.85 | +250.28% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.73 | +852.77% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $67.79 | -40.99% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.21 | +812.05% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.05 | +241.46% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $27.14 | +183.71% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.31 | +12.99% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $53.77 | +41.34% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.59 | +2,038.36% | 4 | May 12, 2022 |
REGENXBIO
Dec 15, 2025
Maintains: Outperform
Price Target: $16 → $20
Current: $13.57
Upside: +47.38%
Ionis Pharmaceuticals
Dec 15, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $79.67
Upside: +25.52%
BridgeBio Pharma
Dec 15, 2025
Maintains: Outperform
Price Target: $75 → $86
Current: $78.24
Upside: +9.93%
Alnylam Pharmaceuticals
Dec 15, 2025
Maintains: Market Perform
Price Target: $370 → $351
Current: $400.17
Upside: -12.29%
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $30.86
Upside: -41.67%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $9.61
Upside: +108.12%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.46
Upside: +102.31%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $21.31
Upside: -53.07%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.20
Upside: +42.86%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $7.32
Upside: +268.85%
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.16
Upside: +257.14%
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $6.00
Upside: +183.33%
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $78.07
Upside: -37.24%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $15.95
Upside: +37.93%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.59
Upside: +3.30%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $17.98
Upside: +61.29%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $4.67
Upside: -14.35%
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $8.85
Upside: +250.28%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.73
Upside: +852.77%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $67.79
Upside: -40.99%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.21
Upside: +812.05%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.05
Upside: +241.46%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $27.14
Upside: +183.71%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.31
Upside: +12.99%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $53.77
Upside: +41.34%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.59
Upside: +2,038.36%